Literature DB >> 20178120

High-level recombinant protein production in CHO cells using lentiviral vectors and the cumate gene-switch.

Bruno Gaillet1, Rénald Gilbert, Sophie Broussau, Amélie Pilotte, Félix Malenfant, Alaka Mullick, Alain Garnier, Bernard Massie.   

Abstract

Fast and efficient production of recombinant proteins for structural and functional studies is a crucial issue for research and for industry. To this end, we have developed an efficient system to generate in less than 2 months, starting from the cDNA, pools of CHO cells stably expressing high-level of recombinant proteins. It is based on lentiviral vectors (LVs) for stable transduction coupled with the cumate gene-switch for inducible and efficient gene expression. Transcription is initiated upon binding of the cumate transactivator (cTA) or the reverse cTA (rcTA) to the CR5 promoter. Binding of cTA or rcTA is prevented or induced by addition of cumate respectively. We first validated the CHO/LV production system with an LV carrying the secreted alkaline phosphatase (SEAP), whose expression was linked to the green fluorescent protein (GFP) through an internal ribosome entry site (IRES). CHO cells stably expressing the cTA (CHO-cTA) were transduced at various multiplicity of infection (MOI). Pools of cells were incubated at 37 and 30 degrees C during 10 days. Optimal SEAP production (65 microg/mL) was achieved at 30 degrees C with a MOI of 200. The pool stability was demonstrated for 48 days of culture by GFP expression analysis. The system was also evaluated using LV expressing three typical therapeutic proteins (a protein made up of the extracellular domain of CD200 fused to IgG Fc region [CD200Fc], a chimeric antibody [chB43], and erythropoietin [EPO]). CHO cells expressing rcTA (CHO-Cum2) were transduced with these LVs at a MOI of 200 and production was tested at 30 degrees C. After 13 days of culture, 235, 160, and 206 microg/mL of CD200Fc, chB43, and EPO were produced, respectively. The ON/OFF ratio of these pools was equal to 6 for CD200Fc, 16 for chB43, and 74 for EPO. In conclusion, this system should be very useful to produce mg quantities of recombinant proteins in a timely manner in serum free suspension culture of CHO cells for preclinical studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20178120     DOI: 10.1002/bit.22698

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  15 in total

1.  Virus-Like Particles Derived from HIV-1 for Delivery of Nuclear Proteins: Improvement of Production and Activity by Protein Engineering.

Authors:  Marc-André Robert; Viktoria Lytvyn; Francis Deforet; Rénald Gilbert; Bruno Gaillet
Journal:  Mol Biotechnol       Date:  2017-01       Impact factor: 2.695

2.  Production and Use of Gesicles for Nucleic Acid Delivery.

Authors:  Mathias Mangion; Marc-André Robert; Igor Slivac; Rénald Gilbert; Bruno Gaillet
Journal:  Mol Biotechnol       Date:  2021-10-01       Impact factor: 2.695

Review 3.  Better and faster: improvements and optimization for mammalian recombinant protein production.

Authors:  Steven C Almo; James D Love
Journal:  Curr Opin Struct Biol       Date:  2014-04-12       Impact factor: 6.809

Review 4.  Protein production from the structural genomics perspective: achievements and future needs.

Authors:  Steven C Almo; Scott J Garforth; Brandan S Hillerich; James D Love; Ronald D Seidel; Stephen K Burley
Journal:  Curr Opin Struct Biol       Date:  2013-05-01       Impact factor: 6.809

Review 5.  Expression vector cassette engineering for recombinant therapeutic production in mammalian cell systems.

Authors:  Tian-Yun Wang; Xiao Guo
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-06       Impact factor: 4.813

Review 6.  Production of Therapeutic Enzymes by Lentivirus Transgenesis.

Authors:  María Celeste Rodríguez; Natalia Ceaglio; Sebastián Antuña; María Belén Tardivo; Marina Etcheverrigaray; Claudio Prieto
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

7.  Daedalus: a robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors.

Authors:  Ashok D Bandaranayake; Colin Correnti; Byoung Y Ryu; Michelle Brault; Roland K Strong; David J Rawlings
Journal:  Nucleic Acids Res       Date:  2011-09-12       Impact factor: 16.971

8.  Lentiviral Vectors Mediate Long-Term and High Efficiency Transgene Expression in HEK 293T cells.

Authors:  Yingying Mao; Renhe Yan; Andrew Li; Yanling Zhang; Jinlong Li; Hongyan Du; Baihong Chen; Wenjin Wei; Yi Zhang; Colin Sumners; Haifa Zheng; Hongwei Li
Journal:  Int J Med Sci       Date:  2015-05-15       Impact factor: 3.738

9.  Analyzing clonal variation of monoclonal antibody-producing CHO cell lines using an in silico metabolomic platform.

Authors:  Atefeh Ghorbaniaghdam; Jingkui Chen; Olivier Henry; Mario Jolicoeur
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

Review 10.  Utilization of Site-Specific Recombination in Biopharmaceutical Production.

Authors:  Maryam Ahmadi; Narges Damavandi; Mohammad Reza Akbari Eidgahi; Fatemeh Davami
Journal:  Iran Biomed J       Date:  2015-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.